Testing Data
(Published customer image: Optimization of secondary antibody staining concentration for detection of CADO48A. Cells were stained with the primary antibody CADO48A alone followed by (a) 1:10 (b) 1:50 and (c) 1:100 dilutions of a secondary FITC antibody. Optimal detection was seen between 1:50 and 1:100 dilution with CADO48A alone. Secondary FITC concentrations of 1:50 (d) and 1:100 (e) to detect CADO48A on pre-labeled CD11b cells were then evaluated and demonstrated that a 1:50 concentration of FITC was optimal for optimal detection of distinct CADO48A+ cells. Based on these findings, a 1:50 FITC concentration was used in all clinical samples. All cells in these diagrams were gated on P1.From: Sherger et al. BMC Veterinary Research 2012 8:209)
Mouse CD11b Monoclonal Antibody | anti-CD11b antibody
MOUSE ANTI DOG CD11b
Immunohistology - Frozen: Application Note: The epitope recognised by this antibody is reported to be sensitive to formaldehyde fixation and tissue processing. MyBioSource recommends the use of acetone fixation for frozen sections.
Flow Cytometry: Maximum Dilution: Neat
Shelf Life: 18 months from date of despatch.
Testing Data
(Published customer image: Optimization of secondary antibody staining concentration for detection of CADO48A. Cells were stained with the primary antibody CADO48A alone followed by (a) 1:10 (b) 1:50 and (c) 1:100 dilutions of a secondary FITC antibody. Optimal detection was seen between 1:50 and 1:100 dilution with CADO48A alone. Secondary FITC concentrations of 1:50 (d) and 1:100 (e) to detect CADO48A on pre-labeled CD11b cells were then evaluated and demonstrated that a 1:50 concentration of FITC was optimal for optimal detection of distinct CADO48A+ cells. Based on these findings, a 1:50 FITC concentration was used in all clinical samples. All cells in these diagrams were gated on P1.From: Sherger et al. BMC Veterinary Research 2012 8:209)
Testing Data
(Published customer image: Optimization of secondary antibody staining concentration for detection of CADO48A. Cells were stained with the primary antibody CADO48A alone followed by (a) 1:10 (b) 1:50 and (c) 1:100 dilutions of a secondary FITC antibody. Optimal detection was seen between 1:50 and 1:100 dilution with CADO48A alone. Secondary FITC concentrations of 1:50 (d) and 1:100 (e) to detect CADO48A on pre-labeled CD11b cells were then evaluated and demonstrated that a 1:50 concentration of FITC was optimal for optimal detection of distinct CADO48A+ cells. Based on these findings, a 1:50 FITC concentration was used in all clinical samples. All cells in these diagrams were gated on P1.From: Sherger et al. BMC Veterinary Research 2012 8:209)
Testing Data
(Published customer image: CD11b+CD14-MHCII- cells suppress T cell proliferation. Facs sorted CD11b+CD14-MHCII- cells isolated from a dog with osteosarcoma or healthy PBMCs were co-incubated with mitogen-stimulated CD4+ and CD8+ T cells isolated from a healthy dog for 72 hs. No stimulated cells were used as negative control. Proliferative responses were measured by 3H-thymidine incorporation from experiments performed in triplicate. CPM, counts per minute. Mean +/- SEM are shown.From: Goulart MR, Pluhar GE, Ohlfest JR (2012) Identification of Myeloid Derived Suppressor Cells in Dogs with Naturally Occurring Cancer. PLoS ONE 7(3): e33274.)
Testing Data
(Published customer image: CD11b+CD14-MHCII- cells suppress T cell proliferation. Facs sorted CD11b+CD14-MHCII- cells isolated from a dog with osteosarcoma or healthy PBMCs were co-incubated with mitogen-stimulated CD4+ and CD8+ T cells isolated from a healthy dog for 72 hs. No stimulated cells were used as negative control. Proliferative responses were measured by 3H-thymidine incorporation from experiments performed in triplicate. CPM, counts per minute. Mean +/- SEM are shown.From: Goulart MR, Pluhar GE, Ohlfest JR (2012) Identification of Myeloid Derived Suppressor Cells in Dogs with Naturally Occurring Cancer. PLoS ONE 7(3): e33274.)
Testing Data
(Published customer image: Flow cytometer analysis of CD11b integrin expression and the binding of Leishmania promastigotes to canine monocytes. (A) Gate R1 was built separating monocytes from animals naturally infected (ANI) with L. chagasi by cells size (x axis) and granularity (y axis). (B) Gate with mononuclear cells (control) (C) CD11b positive cells; (D) CD11b expression during the L. chagasi binding to mononuclear cells with the presence of C5D serum. (E) CD11b expression during the L. chagasi binding to mononuclear cells with the absence of C5D serum.From: Sampaio et al. BMC Veterinary Research 2007 3:11)
Testing Data
(Published customer image: Flow cytometer analysis of CD11b integrin expression and the binding of Leishmania promastigotes to canine monocytes. (A) Gate R1 was built separating monocytes from animals naturally infected (ANI) with L. chagasi by cells size (x axis) and granularity (y axis). (B) Gate with mononuclear cells (control) (C) CD11b positive cells; (D) CD11b expression during the L. chagasi binding to mononuclear cells with the presence of C5D serum. (E) CD11b expression during the L. chagasi binding to mononuclear cells with the absence of C5D serum.From: Sampaio et al. BMC Veterinary Research 2007 3:11)
Testing Data
(Published customer image: Gated myeloid subpopulations evaluated for patient population. All peripheral blood myeloid cells were evaluated using the P1 gate (non-lymphocytes) and subsequently gated based on relatively expression levels of CD11b and CADO48A where CADO48Ahi/CD11bhi (gate P2), CADO48Alow/CD11bhi (gate P3) and CADO48Alow/CD11blow (gate P4) likely represent granulocytes/neutrophils, monocytes and MDSCs, respectively.From: Sherger et al. BMC Veterinary Research 2012 8:209)
Testing Data
(Published customer image: Gated myeloid subpopulations evaluated for patient population. All peripheral blood myeloid cells were evaluated using the P1 gate (non-lymphocytes) and subsequently gated based on relatively expression levels of CD11b and CADO48A where CADO48Ahi/CD11bhi (gate P2), CADO48Alow/CD11bhi (gate P3) and CADO48Alow/CD11blow (gate P4) likely represent granulocytes/neutrophils, monocytes and MDSCs, respectively.From: Sherger et al. BMC Veterinary Research 2012 8:209)
Testing Data
(Published customer image: CD11b+CD14+MHCII- cells demonstrate ability to suppressive T cell proliferation. (A) CD11b+CD14+MHCII- cells were sorted from peripheral blood sample of an osteosarcoma dog (B) and co-cultured with healthy dog PBMCs in the presence of mitogen for 72 hs. Non-stimulated PBMCs were used as negative control and PBMCs co-cultured with healthy PMNs were used to control for the effect of adding cells to the assay. Proliferative responses were measured by 3H-thymidine incorporation. CPM, counts per minute. The experiment was performed in triplicate. Mean +/- SEM are shown.From: Goulart MR, Pluhar GE, Ohlfest JR (2012) Identification of Myeloid Derived Suppressor Cells in Dogs with Naturally Occurring Cancer. PLoS ONE 7(3): e33274.)
Testing Data
(Published customer image: CD11b+CD14+MHCII- cells demonstrate ability to suppressive T cell proliferation. (A) CD11b+CD14+MHCII- cells were sorted from peripheral blood sample of an osteosarcoma dog (B) and co-cultured with healthy dog PBMCs in the presence of mitogen for 72 hs. Non-stimulated PBMCs were used as negative control and PBMCs co-cultured with healthy PMNs were used to control for the effect of adding cells to the assay. Proliferative responses were measured by 3H-thymidine incorporation. CPM, counts per minute. The experiment was performed in triplicate. Mean +/- SEM are shown.From: Goulart MR, Pluhar GE, Ohlfest JR (2012) Identification of Myeloid Derived Suppressor Cells in Dogs with Naturally Occurring Cancer. PLoS ONE 7(3): e33274.)
Testing Data
(Published customer image: Immunophenotyping gating strategy and morphological analysis for MDSC identification in peripheral blood of dogs. PBMCs from healthy dogs and dogs with cancer were stained for the myeloid marker CD11b, monocytic marker CD14 and MHC II. (A) Representative flow cytometric analysis of forward and side scatter and gated CD11b+CD14-MHCII- cells from dogs with advanced or metastatic tumors compared to dogs with early stage non-metastatic tumors and healthy control dogs. Plots are representative of dog with advanced metastatic hemangiosarcoma (top), early stage bladder transitional cell carcinoma (middle) and a healthy dog. (B) FACS sorted CD11b+CD14-MHCII- cells were stained with diff-quick for cell morphology evaluation. A representative example of polymorphonuclear granulocyte morphology of CD11b+CD14-MHCII- cells is shown at 63x magnification.From: Goulart MR, Pluhar GE, Ohlfest JR (2012) Identification of Myeloid Derived Suppressor Cells in Dogs with Naturally Occurring Cancer. PLoS ONE 7(3): e33274.)
Testing Data
(Published customer image: Immunophenotyping gating strategy and morphological analysis for MDSC identification in peripheral blood of dogs. PBMCs from healthy dogs and dogs with cancer were stained for the myeloid marker CD11b, monocytic marker CD14 and MHC II. (A) Representative flow cytometric analysis of forward and side scatter and gated CD11b+CD14-MHCII- cells from dogs with advanced or metastatic tumors compared to dogs with early stage non-metastatic tumors and healthy control dogs. Plots are representative of dog with advanced metastatic hemangiosarcoma (top), early stage bladder transitional cell carcinoma (middle) and a healthy dog. (B) FACS sorted CD11b+CD14-MHCII- cells were stained with diff-quick for cell morphology evaluation. A representative example of polymorphonuclear granulocyte morphology of CD11b+CD14-MHCII- cells is shown at 63x magnification.From: Goulart MR, Pluhar GE, Ohlfest JR (2012) Identification of Myeloid Derived Suppressor Cells in Dogs with Naturally Occurring Cancer. PLoS ONE 7(3): e33274.)
Testing Data
(Published customer image: Increased percentage of CD11blow/CADO48Alow in tumor-bearing canine patients. The expression levels of CD11blow and CADO48Alow was evaluated from the peripheral blood of representative canine patients and show an increase of CD11blow/CADO48low in tumor-bearing canine patients.From: Sherger et al. BMC Veterinary Research 2012 8:209)
Testing Data
(Published customer image: Increased percentage of CD11blow/CADO48Alow in tumor-bearing canine patients. The expression levels of CD11blow and CADO48Alow was evaluated from the peripheral blood of representative canine patients and show an increase of CD11blow/CADO48low in tumor-bearing canine patients.From: Sherger et al. BMC Veterinary Research 2012 8:209)
Testing Data
(Published customer image: Mouse anti-CD11b and Gr-1 antibodies cross-react with canine samples. Fresh PBMCs from healthy dog and cancer patients were isolated by Ficoll, stained with anti-mouse CD11b and anti-mouse Gr-1 antibodies.From: Goulart MR, Pluhar GE, Ohlfest JR (2012) Identification of Myeloid Derived Suppressor Cells in Dogs with Naturally Occurring Cancer. PLoS ONE 7(3): e33274.)
Testing Data
(Published customer image: Mouse anti-CD11b and Gr-1 antibodies cross-react with canine samples. Fresh PBMCs from healthy dog and cancer patients were isolated by Ficoll, stained with anti-mouse CD11b and anti-mouse Gr-1 antibodies.From: Goulart MR, Pluhar GE, Ohlfest JR (2012) Identification of Myeloid Derived Suppressor Cells in Dogs with Naturally Occurring Cancer. PLoS ONE 7(3): e33274.)
Testing Data
(Published customer image: Staining characteristics and evaluation of two commercially available canine granulocytic antibodies of canine peripheral blood. (a) Cells were analyzed according to forward and side scatter. Cells were either gated to include all live and dead (no gate), all live cells including lymphocytes (R1, lymphocytes are circled) and all myeloid cells (P1). (b) Cells were labeled using canine anti-CD11b and either (a) CADO48A or (b) DH59B with the same concentration of secondary antibody FITC. As can be seen in (a), CADO48A allows visualization of an additional cell population as compared to DH59B (b). These results were repeatable with multiple blood samples from different dogs. The cells in (b) were gated on P1 as indicated in (a).From: Sherger et al. BMC Veterinary Research 2012 8:209)
Testing Data
(Published customer image: Staining characteristics and evaluation of two commercially available canine granulocytic antibodies of canine peripheral blood. (a) Cells were analyzed according to forward and side scatter. Cells were either gated to include all live and dead (no gate), all live cells including lymphocytes (R1, lymphocytes are circled) and all myeloid cells (P1). (b) Cells were labeled using canine anti-CD11b and either (a) CADO48A or (b) DH59B with the same concentration of secondary antibody FITC. As can be seen in (a), CADO48A allows visualization of an additional cell population as compared to DH59B (b). These results were repeatable with multiple blood samples from different dogs. The cells in (b) were gated on P1 as indicated in (a).From: Sherger et al. BMC Veterinary Research 2012 8:209)
Testing Data
(Published customer image: Effects of EDTA versus media storage of patient blood samples on flow cytometric results. Peripheral blood cells were (a) stained immediate following collection with CD11b and CADO48A or maintained in EDTA collection tubes for (b) 24 or (c) 48 hours or in media for (d) 24 or (e) 48 hours prior to staining with CD11b and CADO48A. Both EDTA and media samples were kept refrigerated. These findings show a decrease over time of population distinction in EDTA with minimal changes when cells are kept in media up to 48 hours. All cells were gated on P1.From: Sherger et al. BMC Veterinary Research 2012 8:209)
Testing Data
(Published customer image: Effects of EDTA versus media storage of patient blood samples on flow cytometric results. Peripheral blood cells were (a) stained immediate following collection with CD11b and CADO48A or maintained in EDTA collection tubes for (b) 24 or (c) 48 hours or in media for (d) 24 or (e) 48 hours prior to staining with CD11b and CADO48A. Both EDTA and media samples were kept refrigerated. These findings show a decrease over time of population distinction in EDTA with minimal changes when cells are kept in media up to 48 hours. All cells were gated on P1.From: Sherger et al. BMC Veterinary Research 2012 8:209)
NCBI and Uniprot Product Information
Research Articles on CD11b
Similar Products
Product Notes
The CD11b cd11b (Catalog #AAA215215) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. AAA Biotech's CD11b can be used in a range of immunoassay formats including, but not limited to, Immunohistology Frozen*, Flow cytometry (FC/FACS), Immunoprecipitation (IP). Flow Cytometry: Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood Immunohistology - Frozen: Application Note: The epitope recognised by this antibody is reported to be sensitive to formaldehyde fixation and tissue processing. MyBioSource recommends the use of acetone fixation for frozen sections. Flow Cytometry: Maximum Dilution: Neat. Researchers should empirically determine the suitability of the CD11b cd11b for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "CD11b, Monoclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
